Encapsulating therapeutic cells in RGD-modified agarose microcapsules.

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Cell Biology

Background:

• Cell-based therapies offer promise for tissue repair but suffer from poor cell retention at injury sites.
• Hydrogel microcapsules improve cell retention but premature cell escape limits therapeutic benefits.
• Developing strategies to enhance cell adhesion within microcapsules is crucial for effective cell delivery.

Purpose of the Study:

• To develop and evaluate RGD-modified agarose microcapsules for improved cell retention in tissue engineering applications.
• To investigate the effect of cell attachment domains on cell viability, egress, and adhesion post-encapsulation.
• To assess the efficacy of RGD-modified agarose in promoting adhesion of various cell types after egress.

Main Methods:

• Covalent modification of agarose with the arginine, glycine, aspartic acid (RGD) peptide.
• Encapsulation of single cells within 50 μm agarose microcapsules using a microfluidic platform.
• Tracking of cell viability, egress, and attachment at 2, 24, and 48 hours post-encapsulation.

Main Results:

• RGD-modified agarose microcapsules significantly increased the adhesion of egressed cells compared to unmodified agarose.
• NIH 3T3 cells showed nearly 45% attachment to RGD-modified microcapsules after egress.
• Human umbilical vein endothelial cells and cardiac cells also demonstrated substantial attachment (up to 33% and 20%, respectively) to RGD-modified microcapsules.

Conclusions:

• RGD modification of agarose microcapsules enhances cell retention by promoting cell adhesion to the microcapsule surface post-egress.
• This strategy offers a promising approach to overcome cell loss and improve the efficacy of cell-based tissue repair.
• The RGD-modified agarose microcapsule system demonstrates broad applicability for various cell types in regenerative medicine.